[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Terada T: Gastrointestinal stromal tumor of the digestive organs: a histopathologic study of 31 cases in a single Japanese institute. Int J Clin Exp Pathol; 2009;3(2):162-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor of the digestive organs: a histopathologic study of 31 cases in a single Japanese institute.
  • The author herein reports histopathologic features of 31 surgical cases of gastrointestinal stromal tumor (GIST) of the digestive organs.
  • The 31 cases of GIST were diagnosed in our pathology laboratory.
  • They consisted of 24 cases of gastric GIST, 1 case of hepatic GIST, 1 case of small intestinal GIST, 4 cases of colon GIST, and 1 case of rectal GIST.
  • The presenting symptoms were gastrointestinal bleeding in 13 cases, abdominal pain and discomfort in 13 cases, and asymptomatic in 5 cases.
  • Endoscopy and imaging modalities including US, CT and MRI were useful to detect the tumors in all cases, and biopsies confirmed the GIST diagnosis in 21 cases.
  • The size of GIST ranged from 1 cm to 12 cm with a mean of 4.3 cm.
  • Grossly, 23 cases were submucosal tumors, 6 serosa-side tumors, 1 solid tumor in the liver, and 1 rectal polyp.
  • Histologically, 28 cases were of spindle cell type and 3 of epithelioid type.
  • According to mitotic counts and tumor size, the malignant risk was very low in 4 cases, low in 14 cases, intermediate in 9 cases, and high in 4 cases.
  • The 5 cases of GIST were positive for PDGFRA protein, suggesting that PDGFRA overexpression is not associated with PDGFRA gene mutations.
  • The chemotherapy was imatinib mesylate in 6 cases, and none in 25 cases.
  • Four cases of high risk died of GIST, and 27 cases are alive now without tumors.
  • [MeSH-major] Academies and Institutes. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Tract / pathology
  • [MeSH-minor] Actins / metabolism. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Codon. Colonic Neoplasms / pathology. Female. Humans. Immunohistochemistry. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Japan. Liver Neoplasms / pathology. Male. Middle Aged. Point Mutation. Proto-Oncogene Proteins c-kit / metabolism. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Sequence Deletion. Stomach Neoplasms / pathology. Tumor Burden. Vimentin / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Dec 21;14(47):7256-9 [19084944.001]
  • [Cites] Med Oncol. 2009;26(2):233-7 [18777214.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Arch Pathol Lab Med. 2003 Dec;127(12):1606-8 [14632569.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):1-9 [16398673.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):91-102 [17193822.001]
  • [Cites] Int J Gynecol Pathol. 2009 Jan;28(1):29-34 [19047911.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • (PMID = 20126584.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Codon; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ PMC2809996
  • [Keywords] NOTNLM ; GIST / KIT / PDGFRA / clinicopathology / desmin / genetics / immunohisology
  •  go-up   go-down


2. Hiraki M, Kitajima Y, Ohtsuka T, Kai K, Miyake S, Koga Y, Mori D, Noshiro H, Tokunaga O, Miyazaki K: Immunohistochemical and molecular genetic analyses of multiple sporadic gastrointestinal stromal tumors. World J Gastrointest Oncol; 2010 Sep 15;2(9):364-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and molecular genetic analyses of multiple sporadic gastrointestinal stromal tumors.
  • A gastroduodenal endoscopic examination revealed no definitive localized lesions.
  • However, both a large amount of cruor and blood flow from the small intestine into the ascending colon was observed during the colonoscopic examination.
  • At least three tumors, believed to originate from the small intestine, were detected by abdominal computed tomography.
  • Based on these findings, multiple and hemorrhagic small intestinal tumors were diagnosed and surgical treatment of the tumors planned.
  • During the celiotomy, twelve tumors were found in the small intestine.
  • Intestinal wedge or partial resection was applied.
  • All excised specimens demonstrated morphology of a submucosal tumor and the largest tumor had a delle with coagulation on the mucosal face.
  • The immunohistochemical examination revealed that the tumor cells were diffusely positive for KIT and CD34.
  • The myenteric plexus layer of the small intestine was focal-positive for KIT and showed no intestinal cells of Cajal hyperplasia.
  • The tumor sequencing results revealed an identical missense mutation in codon 642 of c-kit exon 13 leading to the replacement of lysine by glutamic acid and a silent germ-line mutation in exon 12 of the PDGFRA gene concerning whole blood, normal mucosa and tumors.
  • We concluded that the current subject was categorized as having multiple sporadic-type gastrointestinal stromal tumor with identical mutational types.
  • Although the patient did not receive any adjuvant chemotherapy, there has been no sign of recurrence over the 3 years since the surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160808.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999140
  • [Keywords] NOTNLM ; Gastrointestinal stromal tumor / Germline mutation / K642E / KIT / Missense mutation / Platelet-derived growth factor receptor a / Surgery / c-kit
  •  go-up   go-down


3. Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY: Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate. World J Gastroenterol; 2006 Jun 21;12(23):3760-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
  • METHODS: Thirty-three of 74 (44.6%) small bowel gastrointestinal stromal tumor (GIST) patients who developed recurrence after curative resection and not treated with Glivec were classified as group A patients.
  • Twenty-two advanced small bowel GIST patients treated with Glivec were classified as group B patients.
  • Each tumor in group B patients was investigated for mutations of kit or platelet-derived growth factor alpha (PDGFRA).
  • The mutation type was correlated with clinical outcomes.
  • The anti-tumor effect and safety of Glivec in group B patients were also assessed.
  • RESULTS: Advanced small bowel GIST patients treated with Glivec had substatntially longer post-recurrence survival and higher overall survival rates than those not treated with Glivec.
  • Glivec induces a sustained objective response in more than half of Asian patients with advanced small bowel GISTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Intestinal Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Exons / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Imatinib Mesylate. Male. Middle Aged. Mutation. Platelet-Derived Growth Factor / genetics. Prognosis. Prospective Studies. Proto-Oncogene Proteins c-kit / genetics. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jul 20;19(31):3521-8 [10918610.001]
  • [Cites] Blood. 2000 Aug 1;96(3):925-32 [10910906.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):317-22 [12949814.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Cancer. 1978 Sep;42(3):1375-84 [81101.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):177-87 [7053814.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):68-77 [1731651.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Am J Surg. 1997 May;173(5):390-4 [9168073.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):297-305 [9891770.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3211-20 [10986053.001]
  • (PMID = 16773696.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4087472
  •  go-up   go-down


Advertisement
4. Miettinen M, Kraszewska E, Sobin LH, Lasota J: A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer; 2008 Feb 1;112(3):645-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.
  • BACKGROUND: Gastrointestinal stromal tumors (GISTs) are KIT-positive mesenchymal tumors of the gastrointestinal tract that are driven by activated KIT-signalling or platelet-derived growth factor receptor-alpha (PDFGRA) signaling.
  • These tumors most commonly occur in the stomach and small intestine and encompass a clinical spectrum from benign to malignant.
  • In the current study, the authors examined long-term follow-up data of 1892 GIST patients from the U.S.
  • BACKGROUND: Nine patients (2 with gastric GISTs and 7 with GISTs of the small intestine) developed myeloid leukemia.
  • RESULTS: The leukemias developed 1.7 to 21 years after the GIST (median interval, 6 years).
  • None of the GIST patients had received radiotherapy or chemotherapy prior to the leukemia diagnosis.
  • Eight of 9 patients died of leukemia, and none died of GIST.
  • All but 1 GIST case was found to have a low mitotic rate (0-1 per 50 high-power fields); however, tumor size varied from 3 to 18 cm (median, 4.5 cm).
  • Standardized incidence ratios (SIRs) and their 95% confidence intervals (95% CIs) were calculated comparing the incidences of AML/CMLs in GIST patients with those in the 2000 through 2003 U.S. population.
  • In GIST patients, the risk of AML was found to be significantly higher for women (SIR of 5.14; 95% CI, 1.34-11.4) and overall (SIR of 2.96; 95% CI, 1.07-5.8).
  • CONCLUSIONS: Additional epidemiologic, clinical, and pathogenetic studies are needed to understand the apparent nonrandom association between GIST and myeloid leukemia.
  • [MeSH-major] Gastrointestinal Stromal Tumors / epidemiology. Intestinal Neoplasms / epidemiology. Leukemia, Myeloid / epidemiology. Stomach Neoplasms / epidemiology


5. Ulusan S, Koç Z, Kayaselçuk F: Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment. Turk J Gastroenterol; 2008 Jun;19(2):129-32
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
  • Our objective was to show the unusual imaging characteristics of cystic liver metastases from a malignant gastrointestinal stromal tumor before and after treatment with imatinib mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / ultrasonography. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Aged. Benzamides. Colon / pathology. Fatal Outcome. Humans. Imatinib Mesylate. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / ultrasonography. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Liver / ultrasonography. Male. Neoplasm Invasiveness. Stomach / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110671.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


6. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP, Besmer P: Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res; 2004 May 15;10(10):3282-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site.
  • PURPOSE: Gastrointestinal stromal tumors (GISTs) are specific KIT expressing and KIT-signaling driven mesenchymal tumors of the human digestive tract, many of which have KIT-activating mutations.
  • Previous studies have found a relatively homogeneous gene expression profile in GIST, as compared with other histological types of sarcomas.
  • EXPERIMENTAL DESIGN: An HG-U133A Affymetrix chip (22,000 genes) platform was used to determine the variability of gene expression in 28 KIT-expressing GIST samples from 24 patients.
  • Statistical analyses (t tests) were performed to identify discriminatory gene lists among various GIST subgroups.
  • The levels of expression of various GIST subsets were also linked to a modified version of the growth factor/KIT signaling pathway to analyze differences at various steps in signal transduction.
  • RESULTS: Genes involved in KIT signaling were differentially expressed among wild-type and mutant GISTs.
  • High gene expression of potential drug targets, such as VEGF, MCSF, and BCL2 in the wild-type group, and Mesothelin in exon 9 GISTs were found.
  • There was a striking difference in gene expression between stomach and small bowel GISTs.
  • This finding was validated in four separate tumors, two gastric and two intestinal, from a patient with familial GIST with a germ-line KIT W557R substitution.
  • CONCLUSIONS: GISTs have heterogeneous gene expression depending on KIT genotype and tumor location, which is seen at both the genomic level and the KIT signaling pathway in particular.
  • These findings may explain their variable clinical behavior and response to therapy.
  • [MeSH-major] Gastrointestinal Neoplasms / genetics. Gastrointestinal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis / methods. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA Mutational Analysis. Exons. Gene Expression Regulation. Genotype. Growth Substances / metabolism. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Intestine, Small / metabolism. Mutation. Nucleic Acid Hybridization. Receptors, Platelet-Derived Growth Factor / genetics. Signal Transduction. Stomach / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15161681.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94503; United States / NHLBI NIH HHS / HL / HL/DK55748; United States / NCI NIH HHS / CA / P01 CA 47179-10A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


7. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol; 2010 Mar 28;16(12):1527-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically treated primary malignant tumor of small bowel: a clinical analysis.
  • AIM: To evaluate the clinical presentation, treatment and survival of patients with primary malignant tumor of small bowel (PMTSB).
  • RESULTS: The most common initial clinical features of the patients were intermittent abdominal discomfort or vague abdominal pain (67.4%), abdominal mass (31.2%), bowel obstruction (24.1%), hemotochezia (21.3%), jaundice (16.3%), fever (14.2%), coexistence of bowel perforation and peritonitis (5.7%), coexistence of gastrointestinal bleeding and shock (5.0%), and intraabdominal bleeding (1.4%).
  • Ileum was the most common site of tumor (44.7%), followed by jejunum (30.5%) and duodenum (24.8%).
  • Segmental bowel resection (n = 81) was the most common surgical procedure, followed by right hemi-colectomy (n = 15), pancreaticoduodenectomy (n = 10), and others (n = 19).
  • Twenty-seven adenocarcinoma patients and 13 malignant lymphoma patients received adjuvant chemotherapy with 5-fluorouracil and cyclophosphamide, adriamycin, vincristine and prednisone, respectively.
  • The median survival time of PMTSB patients was 20.3 mo.
  • Gastrointestinal stromal tumor was observed in 80.0% (20/25), 72.0% (18/25) and 36.0% (9/25) of the patients, respectively.
  • CONCLUSION: En bloc resection is the principal therapy for most PMTSB and chemotherapy is the important treatment modality for malignant lymphoma and other malignant tumors of small bowel which cannot be radically removed.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoid Tumor / surgery. Digestive System Surgical Procedures. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Intestine, Small / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):731-41 [15966194.001]
  • [Cites] Cancer Imaging. 2006;6:209-12 [17208678.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):432-7 [17230614.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):39-45 [17240306.001]
  • [Cites] Chirurgia (Bucur). 2006 Sep-Oct;101(5):477-81 [17278638.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):129-34 [17419246.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2009 Jul;144(7):670-8 [19620548.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83 [12153595.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] Int Surg. 2004 Jan-Mar;89(1):21-6 [15085993.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):995-8 [2705358.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Feb;15(1):46-50 [8082141.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1440-4 [10424748.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • (PMID = 20333796.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846261
  •  go-up   go-down


8. Oku T, Waga E, Sumiyoshi T, Yoshizaki N, Kondo H, Ohira N, Takayama T, Shikishima H, Motohara T: [A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate]. Nihon Shokakibyo Gakkai Zasshi; 2003 Jul;100(7):863-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate].
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Neoplasms / drug therapy. Hemorrhage / etiology. Intestine, Small. Peritoneal Diseases / etiology. Peritoneal Neoplasms / secondary. Piperazines / adverse effects. Pyrimidines / adverse effects
  • [MeSH-minor] Aged. Benzamides. Humans. Imatinib Mesylate. Male. Omentum. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884763.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


9. Yan H, Marchettini P, Acherman YI, Gething SA, Brun E, Sugarbaker PH: Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol; 2003 Jun;26(3):221-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic assessment of gastrointestinal stromal tumor.
  • The term "gastrointestinal stromal tumor" (GIST) has been applied to a collection of distinctive mesenchymal tumors occurring within the human gastrointestinal tract.
  • As new drug therapy becomes available, data regarding the natural history of these unusual tumors are necessary to provide selection factors for treatment.
  • Ninety-eight patients had light microscopy compatible with GIST at a single institution from 1989 to 2000.
  • After immunostaining with c-kit and histopathologic review, 69 were judged to be GIST.
  • All prognostic indicators were determined for gastric GIST, intestinal GIST, and all locations combined.
  • The location of the GIST did not have a significant impact on survival.
  • Clinically, tumor size, peritoneal cancer index, and completeness of cytoreduction had a significant impact on prognosis for GIST at all locations.
  • Pathologically, cytologic atypia, necrosis, invasion and number of mitoses were significant prognostic indicators for GIST.
  • Criteria to separate three pathologic groups of GIST according to the tumor size and the mitotic count were useful to evaluate the tumor behavior; in the borderline pathologic group invasion and cytologic atypia were statistically significant prognostic criteria.
  • The cell phenotypes, as determined by immunostains, correlated with the prognosis of gastric GIST but not intestinal GIST.
  • It is possible to select clinical and pathologic parameters of GIST that impact on prognosis.
  • The immunostain Ki-67 correlated with the prognosis and may be helpful to assess prognosis when dealing with small biopsy specimens.
  • [MeSH-major] Gastrointestinal Neoplasms / mortality. Gastrointestinal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Biomarkers. Desmin / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness. Phenotype. Prognosis. Proto-Oncogene Proteins c-kit / metabolism. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796588.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Desmin; 0 / Ki-67 Antigen; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


10. Yamanaka H, Mizushima T, Mikata S, Ito T, Nonaka K, Ide H, Michiura T, Kainuma S, Iwase K: [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2125-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].
  • The prognosis of metastatic or recurrent GISTs is poor, because these tumors resist chemotherapy and radiotherapy.
  • We report a patient with recurrent GIST who underwent molecularly targeted therapy with imatinib, a novel oral tyrosine kinase inhibitor.
  • The patient had a history of jejunostomy with colostomy for intestinal GIST.
  • The abdominal mass was phi3 x 3.5 cm in size with ascites at Douglas, as determined by computed tomography, and was diagnosed as a peritoneal relapse of GIST.
  • Treatment with imatinib daily was started.
  • After 1 month of treatment with imatinib, reduction of the abdominal tumor began to be recognized on palpation.
  • Computed tomographic scanning at 11 months revealed that the tumor had completely disappeared.
  • The major side effect was drug eruption,which was easily manageable with 2 weeks drug holidays.
  • Imatinib shows promise as a safe and effective drug for the treatment of patients with recurrent GISTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Jejunal Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Drug Administration Schedule. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352942.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


11. Kong M, Wang YL, Xu LJ, Teng XD: [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):617-20
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
  • OBJECTIVE: To study the clinicopathologic features of gastrointestinal stromal tumor (GIST) of small intestine with lymph node metastasis and evaluate the respond to imatinib mesylate (Glivec) therapy.
  • METHODS: Two cases of GIST of small intestine associated with lymph node metastasis were collected and investigated by light microscopy and immunohistochemistry.
  • RESULTS: The cases presented as small intestinal mass of irregular shape.
  • Immunohistochemical study showed that the tumor cells were diffusely distributed and strongly positive for CD117.
  • These two cases were all underwent primary chemotherapy with imatinib mesylate and without new tumor was found during follow-up periods (18, 26 months) after operation.
  • CONCLUSIONS: GIST with nodal metastasis is very rare and needs to be distinguished from other soft tissue sarcomas occurring in this site.
  • The responsiveness to imatinib mesylate therapy correlates with the mutation status of c-kit gene.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Mutation. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Codon. Exons. Follow-Up Studies. Humans. Imatinib Mesylate. Lymphatic Metastasis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079191.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Codon; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


12. Huang CC, Yang CY, Lai IR, Chen CN, Lee PH, Lin MT: Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg; 2009 Apr;33(4):828-34
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era.
  • BACKGROUND: The small intestine, after the stomach, is the second most common primary site for gastrointestinal stromal tumors (GISTs).
  • This study aimed to identify clinicopathologic prognostic factors of tumor recurrence and survival and to analyze the influence of imatinib and sunitinib for small-intestine GISTs.
  • METHODS: We reviewed the surgical experience of patients with small-intestine GISTs at National Taiwan University Hospital from January 1995 to March 2007.
  • We analyzed the perioperative clinicopathologic data and treatment course.
  • The tumor was local in 43 patients, advanced in 21 patients, and 6 had metastasis.
  • The median size of the tumor was 6.5 cm.
  • There were 19 patients with recurrent disease and 6 patients died of intestinal GISTs.
  • According to multivariate analysis for disease recurrence, only invasion status, tumor size, and mitotic rate are significant (P=0.007, 0.035, 0.007 respectively).
  • CONCLUSIONS: The invasion status, size, and mitotic rate of tumor involve higher risk of recurrence and poor survival in small-intestine GISTs.
  • The patients with recurrent small-intestine GISTs may have a lower mortality rate after using imatinib and sunitinib.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Intestinal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Disease-Free Survival. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / pathology. Female. Gastrointestinal Agents / therapeutic use. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / pathology. Infliximab. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):50-9 [11206225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):477-89 [16625094.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Dig Surg. 2008;25(3):208-12 [18577866.001]
  • [Cites] Am Surg. 2006 Aug;72(8):719-22; discussion 722-3 [16913316.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Am J Clin Pathol. 1997 Dec;108(6):641-51 [9384445.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] BMC Gastroenterol. 2006 Oct 24;6:29 [17062131.001]
  • [Cites] J Formos Med Assoc. 2005 Dec;104(12):905-12 [16607447.001]
  • (PMID = 19198935.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


13. Iritani E, Kondo M, Kanemura T, Hara Y, Tagaya E, Tamaoki J, Nagai A: [Drug-induced pneumonia that may have been caused by imatinib mesylate administered for gastrointestinal stromal tumor]. Nihon Kokyuki Gakkai Zasshi; 2007 Jul;45(7):577-81
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug-induced pneumonia that may have been caused by imatinib mesylate administered for gastrointestinal stromal tumor].
  • The patient was a 64-year-old woman who had undergone partial enterectomy for a small intestinal tumor in August 2005, and gastrointestinal stromal tumor (GIST) was diagnosed.
  • Administration of imanitib mesylate was initiated as postoperative chemotherapy in November 2005.
  • Drug-induced pneumonia associated with imatinib mesylate was suspected based on the clinical course, and administration of imatinib mesylate was discontinued.
  • Imatinib mesylate is anticipated to be a good potential therapeutic drug for interstitial pneumonia because it blocks PDGF receptors.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / adverse effects. Pneumonia / chemically induced. Pyrimidines / adverse effects

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682471.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


14. Woodward LM: Management of an enterocutaneous fistula in a patient with a gastrointestinal stromal tumor. J Wound Ostomy Continence Nurs; 2010 May-Jun;37(3):314-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of an enterocutaneous fistula in a patient with a gastrointestinal stromal tumor.
  • BACKGROUND: Gastrointestinal stromal (GIS) tumors are rare malignancies that affect the esophagus, stomach, gallbladder, liver, small intestine, colon, or rectum.
  • These tumors are often refractory to treatment with radiotherapy and chemotherapy and usually treated with a combination of surgery and imatinib mesylate, a tyrosine kinase inhibitor.
  • CASE: This case study describes the management of an enterocutaneous fistula in a patient with a rare GIS tumor who ultimately required radical excision of the mesenteric GIS tumor by enteroenterostomy and colocolostomy.
  • He subsequently developed an enterocutaneous fistula within his dehisced surgical wound.
  • This fistula along with the wound required various dressings and pouching modifications to meet treatment goals and enable the patient to be discharged from the hospital.
  • Fistulas may occur due to the disease or as a result of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Wound Ostomy Continence Nurs. 2010 May-Jun;37(3):318-9 [20463548.001]
  • (PMID = 20463547.001).
  • [ISSN] 1528-3976
  • [Journal-full-title] Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society
  • [ISO-abbreviation] J Wound Ostomy Continence Nurs
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sasaki K, Doi T, Matsumoto G, Tsuruta K, Okamoto A, Funada N: [Metastatic gastrointestinal stromal tumors responded to the treatment with STI571 after polysurgery for recurrent lesions--report of two cases]. Gan To Kagaku Ryoho; 2003 Jul;30(7):1021-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic gastrointestinal stromal tumors responded to the treatment with STI571 after polysurgery for recurrent lesions--report of two cases].
  • Two cases of metastatic gastrointestinal stromal tumors (GIST) that had responded to the treatment with STI571 were presented.
  • Case 1 was a 49-year-old woman who had undergone proximal gastrectomy because of a giant submucosal tumor of the stomach.
  • For 21 months after surgery, the patient received repeated tumor removal four times due to hepatic metastasis and/or peritoneal recurrence.
  • Thereafter, the treatment with STI571 at a dose of 400 mg/day was initiated.
  • Eight months after the administration, only a small hepatic metastasis was detected on a film of CT scan, and any signs of peritoneal recurrence were observed.
  • Case 2 was a 61-year-old man who underwent emergency surgery for a retroperitoneal tumor that had caused massive intestinal hemorrhage resulting in critical shock.
  • The patient underwent the surgery three times for recurrent lesions.
  • Because further tumor removal had become nearly impossible, STI571 at a dose of 400 mg/day was administered 35 months after initial surgery.
  • Six months after treatment the hepatic lesions were shrunk, but the number of retroperitoneal lesions increased.
  • GIST was confirmed in both cases, by histopathological analyses of the resected specimens: positive expression of c-kit and CD34.
  • These clinical observations suggest that ST1571 therapy for metastatic lesions from GIST may be preferred over aggressive, repeated tumor removal.
  • [MeSH-major] Liver Neoplasms / drug therapy. Pyrimidines / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Benzamides. Combined Modality Therapy. Drug Administration Schedule. Female. Gastrectomy. Hepatectomy. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines. Proto-Oncogene Proteins c-kit / analysis. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894723.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


16. Ebrahimi K, Velicković D, Spica B, Sabljak P, Bjelović M, Stojakov D, Micev M, Dunjić M, Pesko P: [Gastrointestinal stromal tumors (GIST) of the stomach as a cause of upper gastrointestinal bleeding]. Acta Chir Iugosl; 2007;54(1):115-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumors (GIST) of the stomach as a cause of upper gastrointestinal bleeding].
  • Gastrointestinal stromal tumors (GIST) is the most common mesenchymal tumor of the gastrointestinal tract.
  • GIST is currently defined as a gastrointestinal tract mesenchymal tumor containing spindle cells (less commonly epitheloid cells or rarely both) and showing CD 117 (c-kit protein) positivity in more than 95% of cases.
  • Although they may arise throughout the gut, the commonest site are stomach (60-70%), small intestine (20-30%), colorectum (5%) and esophagus (up to 5%).
  • GIST originates from the intestinal cell of Cajal (ICC).
  • ICCs are located in and around the myenteric plexus and are thought to function as intestinal pacemaker cells.
  • Historicaly, GIST were often misclassified as leiomyomas or leiomyosarcomas.
  • GIST predominantly occur in middle aged and older patients, with no significant difference in the sex incidence.
  • Clinical presentation of GIST varies widely, and depends on tumor size and location.
  • Commonest symptom of gastric GIST is manifest or occult bleeding.
  • For patient with primary, localized, nonmetastatic GIST, complete surgical resection represents the only chance for cure.
  • Conventional chemotherapy and radiation therapy is ineffective in the treatment of GIST.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Gastrointestinal Stromal Tumors / complications. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633870.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


17. Nakajima M, Toga W: Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor. Nihon Yakurigaku Zasshi; 2003 12;122(6):482-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
  • Bcr-Abl kinase attracted oncology researchers as a molecular target for CML therapy, and a variety of small Abl kinase inhibitors were synthesized.
  • STI571 is also a potent inhibitor of a receptor-type c-Kit tyrosine kinase.
  • Therefore, STI571 was examined for therapeutic efficacy against malignant Gastro-Intestinal Stromal Tumors (GIST), which are mainly caused by aberrant expression of a mutated c-Kit that is constitutively active without binding of a ligand, stem cell factor (SCF).
  • More than a half of the metastatic GIST patients enrolled in the clinical study responded to STI571.
  • Thus, STI571 is now used as a therapeutic drug for both CML and GIST in more than 80 countries worldwide.
  • Therefore, it would be better to make a precise therapeutic strategy with STI571 based on the gene analysis data.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Enzyme Inhibitors / pharmacology. Gastrointestinal Neoplasms / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / pharmacology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14639002.001).
  • [ISSN] 0015-5691
  • [Journal-full-title] Nihon yakurigaku zasshi. Folia pharmacologica Japonica
  • [ISO-abbreviation] Nippon Yakurigaku Zasshi
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 28
  •  go-up   go-down


18. Ryan P, Nguyen VH, Gholoum S, Carpineta L, Abish S, Ahmed NN, Laberge JM, Riddell RH: Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol; 2009 Mar;33(3):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract.
  • PEComa of the gastrointestinal tract, composed of perivascular epithelioid cells with myomelanocytic differentiation, is rare with previous literature limited to 16 case reports.
  • We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy.
  • We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma.
  • We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome.
  • All 4 tumors reporting early recurrence or progression were greater than 5 cm in size and had areas of coagulative tumor necrosis.
  • We propose that a minimum dataset for gastrointestinal PEComa should include these features along with mitotic count, infiltrative border, and tumor stage analogous to that used in colorectal carcinoma.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092636.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Almeida N, Figueiredo P, Lopes S, Gouveia H, Leitão MC: Double-balloon enteroscopy and small bowel tumors: a South-European single-center experience. Dig Dis Sci; 2009 Jul;54(7):1520-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double-balloon enteroscopy and small bowel tumors: a South-European single-center experience.
  • Small bowel tumors are rare, accounting for 1-2% of all gastrointestinal neoplasms.
  • We sought to determine the diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in patients with small bowel tumors.
  • All nine patients (seven males; mean age 68 +/- 11.3 years) with small bowel tumors were retrospectively reviewed.
  • Clinical presentation was: mid-gastrointestinal bleeding or iron-deficient anemia (55.6%); abdominal pain (22.2%); nausea/vomiting and abdominal distension (22.2%).
  • Biopsies were taken in seven patients and provided definitive histological diagnosis in all except one.
  • Final histologic diagnosis were: primary carcinoma (33.3%), gastrointestinal stromal tumor (GIST) (33.3%), malignant lymphoma (22.2%), and carcinoid tumor (11.1%).
  • Mean follow-up time was 15.4 +/- 12.7 months (range 2-34 months).
  • Six patients were submitted to chemotherapy.
  • Small bowel tumors are common in patients submitted to DBE.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Capsule Endoscopy. Constriction, Pathologic. Female. Gastrointestinal Hemorrhage / etiology. Humans. Intestinal Mucosa / pathology. Jejunum / pathology. Male. Middle Aged. Portugal. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2237-43 [17032187.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):114-6 [17630023.001]
  • [Cites] Gastrointest Endosc. 2006 Sep;64(3):445-9 [16923502.001]
  • [Cites] Eur J Radiol. 2007 May;62(2):160-5 [17344005.001]
  • [Cites] Dig Liver Dis. 2006 Dec;38(12):867-78 [17045557.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):49-58 [16429355.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jan;14(1):139-48 [15062387.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):613-5 [17516287.001]
  • [Cites] Endoscopy. 2008 Feb;40(2):140-6 [18253907.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):740-50 [17055868.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):835-7 [17055891.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2217-28 [16762644.001]
  • [Cites] Gastrointest Endosc. 2005 Jun;61(7):826-32 [15933683.001]
  • [Cites] Inflammopharmacology. 2007 Apr;15(2):74-7 [17450446.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):313-6 [16482636.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):408-11 [16680643.001]
  • [Cites] World J Gastroenterol. 2007 Dec 14;13(46):6140-9 [18069752.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2826-32 [17026561.001]
  • [Cites] Dig Liver Dis. 2007 May;39(5):483-7 [17379586.001]
  • [Cites] Surg Endosc. 2007 Oct;21(10):1776-80 [17356941.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):22-7 [16736516.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3 Suppl):S66-8 [17709036.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • (PMID = 18958620.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, Maki RG, Wexler LH, LaQuaglia MP, Besmer P, Antonescu CR: Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol; 2005 Apr;27(4):179-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
  • Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the intestinal tract that typically occur in adults over the age of 40 years.
  • Gene expression analysis was performed on 5 gastric tumor samples from 2 children, 2 gastric tumors from young adults, and 10 gastric GISTs from older adults using an U133A Affymetrix platform (22,000 genes).
  • Although all five patients developed recurrence (four in the liver, three in the peritoneum, and two in both sites), four are still alive with disease.
  • Of the 10 GISTs in young adults, half occurred in the small bowel and had spindle cell morphology, and one case had lymph node metastasis.
  • Seven patients developed recurrence, and at last follow-up two patients had died of disease.
  • GISTs that occur in children are a separate clinicopathologic and molecular subset with predilection for girls, multifocal gastric tumors, and wild-type KIT/PDGFRA genotype.
  • In contrast, GISTs in young adults are a more heterogeneous group, including cases that resemble either the pediatric or the older adult-type tumors.
  • The distinct gene expression profile suggests avenues for investigation of pathogenesis and potential therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Adolescent. Adult. Amino Acid Sequence. Antineoplastic Agents / therapeutic use. Benzamides. Child. DNA Mutational Analysis. Female. Gene Expression Profiling. Humans. Imatinib Mesylate. Male. Molecular Sequence Data. Neoplasm Recurrence, Local / drug therapy. Oligonucleotide Array Sequence Analysis. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Sequence Homology, Amino Acid

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838387.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102774; United States / NCI NIH HHS / CA / CA94503; United States / NHLBI NIH HHS / HL / HL/DK55748; United States / NCI NIH HHS / CA / P01 CA 47179-10A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 39
  •  go-up   go-down


21. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • This tumor rarely develops in the gastrointestinal tract, with no more than 30 cases described in the literature.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • We performed exploratory laparotomy and found at least 15 solid whitish tumors attached to the wall of the small intestine, as well as to the parietal peritoneum.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Hanada N, Kawamura Y, Taneda T, Yoshida Y, Osako T, Inoue K: [A case of recurrent GIST successfully treated with low-dose imatinib mesilate]. Gan To Kagaku Ryoho; 2006 Jun;33(6):799-801
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent GIST successfully treated with low-dose imatinib mesilate].
  • A 75-year-old man underwent partial resection of the small intestine for GIST in January 2000.
  • A recurrent tumor revealed in the intra pelvic space was removed by two operations, and imatinib (400 mg/day) was given after the third operation.
  • As successive administration was not able to be continued due to side effects such as anorexia and fatigue, the recurrent tumor enlarged.
  • After imatinib was given at 200 mg/day, the defecation trouble was improved and the tumor decreased partially on CT image.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Gastrointestinal Stromal Tumors / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small. Neoplasm Recurrence, Local / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Aged. Benzamides. Drug Administration Schedule. Humans. Imatinib Mesylate. Male. Pelvis. Point Mutation. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770100.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


23. Takashima M, Igaki N, Matsuda T, Ohyama M, Kanda S, Tamada F, Goto T: Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate. Intern Med; 2005 Feb;44(2):114-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate.
  • We describe a patient who had a metastatic gastrointestinal stromal tumor (GIST) after previous failed extensive therapy, including multiple surgeries and hepatic artery embolization.
  • Within a few months of starting administration of imatinib mesylate, the patient exhibited a clinical response with grade 3 neutropenia, when pulmonary tuberculosis developed.
  • It is unclear whether or not pulmonary tuberculosis may be induced by imatinib mesylate treatment, but caution is warranted in immunocompromised GIST patients.
  • This is the first report of tuberculosis associated with neutropenia during imatinib mesylate treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Stromal Tumors / complications. Jejunal Neoplasms / complications. Leiomyosarcoma / complications. Piperazines / adverse effects. Pyrimidines / adverse effects. Tuberculosis, Pulmonary / complications
  • [MeSH-minor] Administration, Oral. Antitubercular Agents / therapeutic use. Benzamides. Combined Modality Therapy. Digestive System Surgical Procedures. Fatal Outcome. Humans. Imatinib Mesylate. Laparotomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / complications. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750270.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antitubercular Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


24. Ronchi CL, Coletti F, Fesce E, Montefusco L, Ogliari C, Verrua E, Epaminonda P, Ferrante E, Malchiodi E, Morelli V, Beck-Peccoz P, Arosio M: Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly. J Endocrinol Invest; 2009 Jun;32(6):495-500
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly.
  • An epidemiological study suggests a high prevalence also of small bowel (SB) tumors that nowadays may be detected by videocapsule endoscopy (VCE).
  • Eighteen acromegalic patients (6 males and 12 females, age+/-SD: 54+/-10 yr), 5 cured after surgery (followed by radiotherapy in 3 cases) and 13 on pharmacological treatment were enrolled, and 36 sex- and age-matched non-acromegalic subjects served as a control group.
  • Cancer risk factors, duration of acromegaly, GH and IGF-I levels, IGF binding protein 3 and IGF-II concentrations, metabolic parameters, tumor markers, colonic lesions by total colonoscopy, and SB lesions by VCE were investigated.
  • VCE images suggestive of SB lesions were detected in 5/36 controls [14%, 4 described as gastrointestinal stromal nodular tumors (GIST), and 1 as polyp] and in 5/18 acromegalic patients [28%, 2 GIST and 3 polyps].
  • [MeSH-major] Acromegaly / complications. Capsule Endoscopy / methods. Intestinal Neoplasms / complications. Intestinal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2237-43 [17032187.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3402-8 [10999841.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1154-60 [15842593.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3854-60 [17652220.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jan;93(1):61-7 [17971431.001]
  • [Cites] Eur J Endocrinol. 2005 Mar;152(3):443-8 [15757862.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):49-58 [16429355.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):203-20 [15650828.001]
  • [Cites] Rev Endocr Metab Disord. 2008 Mar;9(1):41-58 [18157698.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):84-90 [15507515.001]
  • [Cites] Horm Metab Res. 2006 May;38(5):352-5 [16718634.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):667-74 [14764779.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):27-37 [15654777.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Aug;55(2):183-9 [11531924.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):218-23 [17047386.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):960-5 [16189768.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):712-25 [14710350.001]
  • [Cites] Nutrition. 2000 Apr;16(4):245-54 [10758358.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1351-6 [16449330.001]
  • [Cites] Rev Endocr Metab Disord. 2008 Mar;9(1):33-9 [18075787.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Mar;37(1):101-22, viii [18226732.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):2929-34 [11443145.001]
  • [Cites] Cancer Causes Control. 2002 Jun;13(5):395-400 [12146843.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):59-66 [16429356.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):52-7 [16405533.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):999-1005 [12360460.001]
  • [Cites] Gut. 2005 May;54(5):630-5 [15831907.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1377-82 [15585548.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jul;47(1):17-22 [9302367.001]
  • [Cites] Cancer. 1991 Oct 15;68(8):1673-7 [1913507.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4 [9709939.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):22-7 [16736516.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • [Cites] Intern Med J. 2005 Apr;35(4):234-9 [15836502.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • (PMID = 19494714.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / IGF2 protein, human; 0 / IGFBP3 protein, human; 0 / Insulin; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Proteins; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


25. Antonescu CR: Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol; 2008 May;21 Suppl 2:S31-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas.
  • Once a poorly understood pathologic entity, gastrointestinal stromal tumor (GIST) has emerged in recent years as a distinct oncologic-molecular paradigm that is now a leading model for kinase-targeted therapies in oncology.
  • A small subset of GIST show activating mutations in PDGFRA, encoding a related member of the type III receptor tyrosine kinase family.
  • The revelation of KIT expression as a diagnostic signature of GIST has not only revolutionized the pathologic criteria in classifying GIST, but also shed light on the histogenesis of these tumors.
  • The similarities in KIT immunoreactivity and ultrastructural appearance between GISTs and the intestinal pacemaker, the interstitial cells of Cajal (ICC), suggested that GISTs derive from or differentiate toward the ICC lineage.
  • This review will include a summary of the biology behind the specific targeted therapies, emphasizing the central role of KIT and PDGFRA oncogenic mutations in GISTs and their clinical and pathologic correlates.
  • The role of KIT immunohistochemistry vs mutation testing will be discussed, with an insight into the indications for KIT/PDGFRA genotyping in GIST.
  • The morphologic and molecular changes that appear with imatinib treatment, such as response and acquired imatinib resistance, are being discussed.
  • The success GIST story based on targeted molecular paradigm may be applied in other imatinib-responsive sarcoma, such as dermatofibrosarcoma protuberans.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems / trends. Gastrointestinal Stromal Tumors / drug therapy. Pathology, Clinical / trends. Sarcoma / drug therapy
  • [MeSH-minor] Biomarkers, Tumor / genetics. Humans. Physicians. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437171.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 40
  •  go-up   go-down






Advertisement